SNOA — Sonoma Pharmaceuticals Balance Sheet
0.000.00%
- $4.88m
- -$0.27m
- $14.29m
- 48
- 63
- 70
- 63
Annual balance sheet for Sonoma Pharmaceuticals, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 4.22 | 7.4 | 3.82 | 3.13 | 5.37 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 4.66 | 4.78 | 6.42 | 5.99 | 3.76 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 13 | 16.4 | 13.8 | 12.5 | 12.6 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.13 | 0.879 | 0.906 | 0.651 | 0.309 |
Other Long Term Assets | |||||
Total Assets | 15 | 18.8 | 16.2 | 14.7 | 13.7 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4.08 | 5.82 | 3.72 | 3.72 | 4.1 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 9.62 | 10.1 | 8.25 | 8.6 | 9.28 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 5.36 | 8.7 | 7.98 | 6.14 | 4.41 |
Total Liabilities & Shareholders' Equity | 15 | 18.8 | 16.2 | 14.7 | 13.7 |
Total Common Shares Outstanding |